Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02388906 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
A Phase 3 study of Melanoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 906
- Enrollment target
- 20
- Study locations
NCT02388906 is a Phase 3 study of Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 906 participants, above the 703-participant average among 266 other Melanoma trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT02388906, a Phase 3 study of Melanoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 906 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- OTHER Placebo matching Ipilimumab
- OTHER Placebo matching Nivolumab
Study Locations (20)
California
- Local Institution - 0117 - La Jolla
- Local Institution - 0189 - Los Angeles
- Local Institution - 0021 - San Francisco
- Local Institution - 0006 - San Francisco
Florida
- Local Institution - 0012 - Jacksonville
- Local Institution - 0019 - Miami Beach
- Local Institution - 0030 - Orlando
- Local Institution - 0032 - Tampa
Massachusetts
- Local Institution - 0013 - Boston
- Local Institution - 0170 - Boston
- Local Institution - 0171 - Boston
Arkansas
- Local Institution - 0036 - Little Rock
Colorado
- Local Institution - 0010 - Aurora
District of Columbia
- Local Institution - 0004 - Washington D.C.
Georgia
- Local Institution - 0016 - Atlanta
Illinois
- Local Institution - 0106 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 906 participants |
| Start Date | 2015-03-16 |
| Est. Completion | 2024-10-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02388906
The ClinicalTrials.gov registry entry for NCT02388906 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 906 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 703-participant average among 266 other Melanoma trials with a reported enrollment target (29% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT02388906 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02388906 about?
NCT02388906 is a clinical study titled "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma". The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.
What is the current status of trial NCT02388906?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 906 participants. The study started on 2015-03-16. Estimated completion is 2024-10-16.
What conditions does trial NCT02388906 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT02388906?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Placebo matching Ipilimumab (OTHER), Placebo matching Nivolumab (OTHER).
Who is sponsoring clinical trial NCT02388906?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02388906 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RECRUITING · Phase 3
-
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RECRUITING · Phase 3
-
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
ACTIVE NOT RECRUITING · Phase 3
-
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.